FDA Approved New PAH Drug from Actelion

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email


According to a recent announcement, the United States Food and Drug Administration (FDA) approved Actelion Pharmaceuticals’ Uptravi (selexipag) tablets for the treatment of adult patients with pulmonary arterial hypertension (PAH) to delay disease progression and reduce the risk of hospitalization, under orphan drug designation.

PAH is a life-threatening disease characterized by high blood pressure and abnormal constriction of the pulmonary artery. The condition causes the heart to work faster and elevates blood pressure in arteries within the lungs, potentially causing fatal heart failure and other, less serious, complications and disturbances in quality of life.


Read more about it: http://bit.ly/1Jrfx5F